.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Julphar
Cerilliant
Accenture
Argus Health
QuintilesIMS
Chinese Patent Office
Dow
Healthtrust
Cantor Fitzgerald
Merck

Generated: September 21, 2017

DrugPatentWatch Database Preview

Claims for Patent: ► Subscribe

« Back to Dashboard

Claims for Patent: ► Subscribe

Title:Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a pH control agent
Abstract: The present invention provides a solid pharmaceutical composition containing compound (I) having an angiotensin II receptor antagonistic action and defined in the specification and a pH control agent, which composition is superior in the stability and dissolution property of compound (I).
Inventor(s): Yoneyama; Shuji (Osaka, JP), Tanoue; Yutaka (Osaka, JP)
Assignee: Takeda Pharmaceutical Company Limited (Osaka, JP)
Application Number:12/450,403
Patent Claims: 1. A solid pharmaceutical composition comprising a compound which is (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]met- hyl}-1H-benzimidazole-7-carboxylate potassium salt and a solid pH control agent which provides a pH of 3 to 5 when dissolved or suspended in water at a concentration of 1% w/v at 25.degree. C.

2. The pharmaceutical composition of claim 1, wherein the pH control agent is monosodium fumarate or a combination of fumaric acid and sodium hydroxide.

3. A method of stabilizing a compound which is (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]met- hyl}-1H-benzimidazole-7-carboxylate potassium salt in a solid pharmaceutical composition or improving dissolution of a compound which is (5-methyl-2-oxo-1,3-dioxol-4-yl)methyl 2-ethoxy-1-{[2'-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]met- hyl}-1H-benzimidazole-7-carboxylate potassium salt from a solid pharmaceutical composition, which comprises adding a pH control agent having a pH of 3 to 5 when dissolved or suspended in water at a concentration of 1% w/v at 25.degree. C. to the solid pharmaceutical composition comprising the compound.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Federal Trade Commission
Queensland Health
Express Scripts
Fuji
Covington
Citi
AstraZeneca
McKesson
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot